Profile
Sector:
HealthcareIndustry:
Drug Manufacturers - GeneralCountry:
United KingdomIPO:
12 May 1993Website:
http://www.astrazeneca.comNext earnings report:
25 July 2024Last dividends:
22 February 2024Next dividends:
N/APrice
after hours | 100 min agoAnalysts recommendations
Institutional Ownership
AZN Latest News
While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven't considered the sector, it's really time to focus on biotech stocks.
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said on Wednesday.
AstraZeneca PLC (LSE:AZN) has put out mixed data for the Phase III trials of its immuno-oncology (IO) drug Imfinzi, notes broker ShoreCap. There was a positive result from the Phase III NIAGARA trial looking at its use perioperatively (either side of surgery) for the treatment of bladder cancer (MIBC).
AstraZeneca PLC (LSE:AZN) shared some disappointing news on an advanced lung cancer trial of its Imfinzi immunotherapy. Phase III trials showed the drug did not achieve statistical significance for its primary endpoint of disease-free survival compared to placebo in early-stage non-small cell lung cancer.
BenevolentAI (OTC:BAIVF) said that AstraZeneca PLC (LSE:AZN) has identified a target for systemic lupus erythematosus (SLE) using the former's artificial intelligence-driven drug discovery platform - the second asset selected as part of a collocation the pair have. Benevolent's tie-up with AZ began in 2019, focusing on idiopathic pulmonary fibrosis and chronic kidney disease.
AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.
AstraZeneca should have lots of growth ahead. Bristol Myers Squibb has what it takes to navigate a major patent cliff.
The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.
AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patients with a type of breast cancer.
What type of business is AstraZeneca?
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
What sector is AstraZeneca in?
AstraZeneca is in the Healthcare sector
What industry is AstraZeneca in?
AstraZeneca is in the Drug Manufacturers - General industry
What country is AstraZeneca from?
AstraZeneca is headquartered in United Kingdom
When did AstraZeneca go public?
AstraZeneca initial public offering (IPO) was on 12 May 1993
What is AstraZeneca website?
https://www.astrazeneca.com
Is AstraZeneca in the S&P 500?
No, AstraZeneca is not included in the S&P 500 index
Is AstraZeneca in the NASDAQ 100?
Yes, AstraZeneca is included in the NASDAQ 100 index
Is AstraZeneca in the Dow Jones?
No, AstraZeneca is not included in the Dow Jones index
When does AstraZeneca report earnings?
The next expected earnings date for AstraZeneca is 25 July 2024